http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9e3f9afaabf94fc51f767c0d1f6158de
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Myers |
| name | Andrea P Myers Andrea P. Myers |
| given-name | Andrea P. Andrea P |
| organization-name | Authors' Affiliations: Departments of 1Systems Biology, 2Bioinformatics and Computational Biology, 3Gynecologic Oncology, and 4Pathology, The University of Texas MD Anderson Cancer Center; 5Department of Molecular and Human Genetics, Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas; 6Department of Medical Oncology, Beaumont Hospital; 7Royal College of Surgeons of Ireland, Dublin, Ireland; 8Division of Women's Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute; 9Division of Signal Transduction, Department of Medicine, Beth Israel Deaconess Medical Center; 10Department of Systems Biology, Harvard Medical School, Boston, Massachusetts; and 11Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Ontario, Canada; Authors' Affiliations: Departments of 1Systems Biology, 2Bioinformatics and Computational Biology, 3Gynecologic Oncology, and 4Pathology, The University of Texas MD Anderson Cancer Center; 5Department of Molecular and Human Genetics, Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas; 6Department of Medical Oncology, Beaumont Hospital; 7Royal College of Surgeons of Ireland, Dublin, Ireland; 8Division of Women's Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute; 9Division of Signal Transduction, Department of Medicine, Beth Israel Deaconess Medical Center; 10Department of Systems Biology, Harvard Medical School, Boston, Massachusetts; and 11Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Ontario, Canada Gynecologic Oncology Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Division of Hematology/Oncology, Department of Medical Oncology Dana Farber Cancer Institute Boston MA Authors' Affiliations: 1Department of Medical Oncology, Dana Farber Cancer Institute; 2Division of Signal Transduction, Beth Israel Deaconess Medical Center; and 3Department of Systems Biology, Harvard Medical School, Boston, Massachusetts; Authors' Affiliations: 1Department of Medical Oncology, Dana Farber Cancer Institute; 2Division of Signal Transduction, Beth Israel Deaconess Medical Center; and 3Department of Systems Biology, Harvard Medical School, Boston, Massachusetts Authors' Affiliations: 1Gynecology Oncology Program, Division of Women's Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute; and 2Division of Signal Transduction, Department of Medicine, Beth Israel Deaconess Cancer Center, Boston, Massachusetts; Authors' Affiliations: 1Gynecology Oncology Program, Division of Women's Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute; and 2Division of Signal Transduction, Department of Medicine, Beth Israel Deaconess Cancer Center, Boston, Massachusetts Department of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts; Harvard Medical School Boston Massachusetts Authors' Affiliations: 1Department of Cancer Biology; 2Division of Women's Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute; Departments of 3Biological Chemistry and Molecular Pharmacology and 4Systems Biology; 5Rodent Histopathology Core, DF/HCC, Harvard Medical School; 6Department of Surgery, Brigham and Women's Hospital; 7Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston; 8Novartis Institutes for Biomedical Research, Cambridge, Massacheusetts; 9Department of System Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Novartis Institutes for Biomedical Research, Oncology Disease Area, Novartis Pharma AG, Basel, Switzerland; Authors' Affiliations: 1Department of Cancer Biology; 2Division of Women's Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute; Departments of 3Biological Chemistry and Molecular Pharmacology and 4Systems Biology; 5Rodent Histopathology Core, DF/HCC, Harvard Medical School; 6Department of Surgery, Brigham and Women's Hospital; 7Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston; 8Novartis Institutes for Biomedical Research, Cambridge, Massacheusetts; 9Department of System Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Novartis Institutes for Biomedical Research, Oncology Disease Area, Novartis Pharma AG, Basel, Switzerland Authors' Affiliations: 1Division of Hematology-Oncology, University of California Irvine Medical Center, Orange, California; 2Division of Signal Transduction, Beth Israel Deaconess Medical Center; 3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; and 4Department of Medicine, Weill Cornell Medical College, New York, New York; Authors' Affiliations: 1Division of Hematology-Oncology, University of California Irvine Medical Center, Orange, California; 2Division of Signal Transduction, Beth Israel Deaconess Medical Center; 3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; and 4Department of Medicine, Weill Cornell Medical College, New York, New York Division of Women’s Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Division of Signal Transduction, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA. |
Incoming Links
Showing number of triples: 1 to 29 of 29.